Literature DB >> 1696634

Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody.

T H Bugge1, B O Lindhardt, L L Hansen, P Kusk, E Hulgaard, K Holmbäck, P J Klasse, J Zeuthen, K Ulrich.   

Abstract

A human monoclonal antibody, 41-7 [immunoglobulin G1(kappa)], directed against the transmembrane glycoprotein gp41 of the human immunodeficiency virus type 1 (HIV-1) has been produced by direct fusion of lymph node cells from an HIV-1-infected individual with a human B-lymphoblastoid cell line. The minimal essential epitope for 41-7 was mapped to a conserved seven-amino acid sequence, N-CSGKLIC-C, located within the N-terminal part of gp41. Antibodies blocking the binding of 41-7 could be detected in the serum of all HIV-1-infected individuals tested, irrespective of the stage of the infection. The epitope is located externally to the plasma membrane, and it is accessible to antibody in the native conformation of the glycoprotein. Despite this, no neutralizing activity of 41-7 could be demonstrated in vitro. These data indicate, directly and indirectly, that this immunodominant epitope on gp41, although exposed on the viral surface, elicits antibodies lacking antiviral activity and, hence, should be avoided in future vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696634      PMCID: PMC247875     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Characterization of serum neutralization response to the human immunodeficiency virus (HIV).

Authors:  J E Groopman; P M Benz; R Ferriani; K Mayer; J D Allan; L A Weymouth
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

2.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

3.  A simple immunoblotting method after separation of proteins in agarose gel.

Authors:  C Koch; K Skjødt; I Laursen
Journal:  J Immunol Methods       Date:  1985-11-28       Impact factor: 2.303

4.  Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.

Authors:  M A Till; S Zolla-Pazner; M K Gorny; J S Patton; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

6.  Construction of plasmid cloning vehicles that promote gene expression from the bacteriophage lambda pL promoter.

Authors:  H U Bernard; E Remaut; M V Hershfield; H K Das; D R Helinski; C Yanofsky; N Franklin
Journal:  Gene       Date:  1979-01       Impact factor: 3.688

7.  Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.

Authors:  S L Hu; P N Fultz; H M McClure; J W Eichberg; E K Thomas; J Zarling; M C Singhal; S G Kosowski; R B Swenson; D C Anderson
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

8.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

10.  Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

Authors:  P W Berman; J E Groopman; T Gregory; P R Clapham; R A Weiss; R Ferriani; L Riddle; C Shimasaki; C Lucas; L A Lasky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

View more
  7 in total

1.  Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.

Authors:  V Boyer; H Broly; S Souche; P Madaule; J Rossier; D Zagury; C Desgranges
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Autologous antibody response against the principal neutralizing domain of human immunodeficiency virus type 1 isolated from infected humans.

Authors:  K Holmbäck; P Kusk; E F Hulgaard; T H Bugge; E Scheibel; B O Lindhardt
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

4.  Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.

Authors:  T M Richardson; B L Stryjewski; C C Broder; J A Hoxie; J R Mascola; P L Earl; R W Doms
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Structural analysis of the principal immunodominant domain of the feline immunodeficiency virus transmembrane glycoprotein.

Authors:  G Pancino; L Camoin; P Sonigo
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

6.  Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.

Authors:  S Zolla-Pazner; J O'Leary; S Burda; M K Gorny; M Kim; J Mascola; F McCutchan
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

7.  Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs.

Authors:  Kristen C Witt; Luis Castillo-Menendez; Haitao Ding; Nicole Espy; Shijian Zhang; John C Kappes; Joseph Sodroski
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.